BAX Add to watchlist $21.80 0.77 (-3.41%) Last updated: Jul 15, 2026 06:03
52-Week Range
$21.80
$15.73 $21.80 $29.35

Fundamentals Overview

Baxter International Inc. is in the middle of its 52-week range with low valuation, trending downward today.

Valuation low

P/B 1.86 P/S 0.99

Risk (Beta)

0.61 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 57% confidence Risk: Lower Volatility — Beta 0.61. Diversify and only invest what you can afford to lose.

Supporting (Buy):

3M vs S&P 500: +14.1% · 3M vs Healthcare sector: +16.7%

Pressures (Sell):

Sentiment weakening (3 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$11.26B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
0.92%
52-Week Range
$15.73 - $29.35
Volume vs Avg
N/A
Beta
0.61

About

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixe...
Sector: Healthcare
Headquarters: US
Employees: 37,500
IPO Date: Oct 1981
Beta: 0.61 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 1, Equal Weight: 2, Hold: 2, Neutral: 12, Outperform: 4, Overweight: 5, Sell: 1, Underweight: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-3.71; current price is $21.80. That’s a -117% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 1.86
P/S (TTM) 0.99
P/FCF (TTM) 15.77
Liquidity & enterprise
Current Ratio (TTM) 1.85
Quick Ratio (TTM) 1.23
Cash Ratio (TTM) 0.55
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -9.7%
Gross margin (TTM) 30.11%
Operating margin (TTM) -2.65%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BAX.

Analyst Sentiment at a Glance

C+ Sentiment Weakening
Buy 1Equal Weight 2Hold 2Neutral 12Outperform 4Overweight 5Sell 1Underweight 3
0 upgrades, 3 downgrades
Price Target Consensus
Current $21.80
Median $20.00
Consensus $20.86
Low consensus $17.00
High consensus $27.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-07-06
Citigroup downgrade Neutral Sell 2026-05-28
Barclays maintain Overweight Overweight 2026-05-04
Evercore ISI Group maintain Outperform Outperform 2026-04-06
Citigroup maintain Neutral Neutral 2026-03-11
Goldman Sachs maintain Neutral Neutral 2026-02-17
Barclays maintain Overweight Overweight 2026-02-13
Barclays maintain Overweight Overweight 2026-01-09
Morgan Stanley maintain Underweight Underweight 2025-12-02
Goldman Sachs maintain Neutral Neutral 2025-10-31
Argus Research downgrade Buy Hold 2025-10-31
UBS maintain Neutral Neutral 2025-10-31
Citigroup maintain Neutral Neutral 2025-10-31
Evercore ISI Group maintain Outperform Outperform 2025-10-07
UBS maintain Neutral Neutral 2025-08-04
Barclays maintain Overweight Overweight 2025-08-04
Stifel downgrade Buy Hold 2025-08-04
Wells Fargo maintain Equal Weight Equal Weight 2025-08-01
Morgan Stanley maintain Underweight Underweight 2025-07-15
Citigroup maintain Neutral Neutral 2025-07-09
Evercore ISI Group maintain Outperform Outperform 2025-07-08
Morgan Stanley maintain Underweight Underweight 2025-05-05
Wells Fargo maintain Equal Weight Equal Weight 2025-05-02
Barclays maintain Overweight Overweight 2025-03-10
JP Morgan maintain Neutral Neutral 2025-02-21
Citigroup maintain Neutral Neutral 2024-12-11
Stifel maintain Buy Buy 2024-11-11
Citigroup maintain Neutral Neutral 2024-10-01
Goldman Sachs maintain Neutral Neutral 2024-08-08
JP Morgan maintain Neutral Neutral 2024-08-07